Edition:
United States

People: Alkermes Plc (ALKS.O)

ALKS.O on Nasdaq

58.47USD
23 Jun 2017
Change (% chg)

-- (--)
Prev Close
$58.47
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
880,548
52-wk High
$63.40
52-wk Low
$39.65

Dixon, Wendy 

Dr. Wendy L. Dixon Ph.D. is Independent Director of Alkermes Plc. She has extensive experience in the pharmaceutical and biotechnology industries, combining a technical background with experience in drug development, regulatory affairs and marketing. She directed the launches and growth of more than 20 pharmaceutical products. From 2001 to 2009 she was Chief Marketing Officer and President, Global Marketing for Bristol-Myers Squibb where she served on the Executive Committee. From 1996 to 2001 she was Senior Vice President, Marketing at Merck, and prior to that, she held executive management positions at West Pharmaceuticals, Osteotech and Centocor and various positions at SmithKline and French (now GlaxoSmithKline) in marketing, regulatory affairs, project management and as a biochemist. Dr. Dixon is on the board of directors of Incyte Corporation, bluebird bio and Eleven Biotherapeutics, all publicly traded biotechnology or pharmaceutical companies, and was formerly on the board of Ardea Biosciences, Dentsply International, Edimer Pharmaceuticals, Furiex Pharmaceuticals and Orexigen Therapeutics. She is an advisor to the Mellon Group and a member of the Longitude Capital Industry Advisory Board. She was a Senior Advisor to The Monitor Group, now Deloitte, from 2010 to 2012. She also serves on the board of Special Equestrians, a non-profit. Qualifications and Skills: Dr. Dixon brings a depth of experience in the marketing of pharmaceutical products across a broad variety of disease states and on a global basis to our Board. Dr. Dixon has a strong technical background and direct experience in product development and regulatory affairs, and has successfully built and grown commercial organizations in the United States and Europe, each of which provide valuable insight to our Board regarding the development and commercialization of pharmaceutical products.

Basic Compensation

Total Annual Compensation, USD 89,000
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 370,642
Fiscal Year Total, USD 459,642

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Richard Pops

12,407,500

Shane Cooke

5,087,350

James Frates

3,149,310

Kathryn Biberstein

4,333,980

Elliot Ehrich

4,356,340

Craig Hopkinson

--
As Of  30 Dec 2015